SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SpaceX engineers reusable launch vehicles and the Starlink satellite constellation for global broadband. Their focus on rapid reusability and vertical integration drives down launch costs and accelerates space access.

SpaceX PreStocks

Investors are actively debating the legitimacy of a tokenized crypto asset claiming to represent SpaceX, with many warning it is a scam while others speculate on its connection to the company's long-rumored IPO. The community conversation is dominated by intense skepticism regarding unauthorized tokens, contrasted with broader market excitement surrounding SpaceX's expected public debut and its potential impact on space-sector stocks.

Uranium Energy Corp. engages in the provision of uranium and titanium mining and related activities, including exploration, pre-extraction, extraction, and processing of uranium concentrates, and titanium minerals. It operates through the following geographical segments: Wyoming, Texas, Saskatchewan, and Others. The company was founded by Alan P. Lindsay and Amir Adnani on May 16, 2003 and is headquartered in Corpus Christi, TX.

Uranium Energy Corp

Uranium Energy Corp is trending as investors focus on its U.S.-based ISR production ramp-up, with community discussions highlighting its potential to capture rising demand from AI-driven data center power needs. The stock is seeing heavy attention amid a broader nuclear energy narrative, as market participants monitor institutional accumulation and upcoming earnings in anticipation of a potential sector-wide squeeze.

USDX is the crypto-backed native stablecoin of the Kava DeFi hub.

USDX Stablecoin

The USDX is currently a focal point for technical analysts utilizing Elliott Wave theory, with the community actively debating whether the index is consolidating within a corrective triangle or preparing for a broader trend shift. Traders are closely monitoring the dollar's interaction with key support and resistance levels while gauging how correlated moves in major pairs like the GBPUSD and USDJPY will influence the index's next structural move.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is generating significant buzz as investors weigh the company's aggressive AI and cloud infrastructure pivot against upcoming earnings and high-stakes geopolitical trade talks. While the community is split between bullish sentiment over long-term AI potential and skepticism surrounding recent earnings volatility, attention is heavily focused on whether institutional positioning will trigger a re-rating for the stock.

Evolution Metals & Technologies Corp. engages in developing a global supply chain for critical minerals and materials. It focuses on automotive, renewable energy, and military and defense sectors. The company is headquartered in West Palm Beach, FL.

Evolution Metals & Technologies Corp.

Evolution Metals & Technologies Corp. Common Stock

Evolution Metals & Technologies is drawing significant investor interest due to its pivot toward a vertically integrated U.S. supply chain for critical minerals and rare earth magnets, which community members view as a strategic hedge against international trade tensions. While some participants are wary of potential volatility and bot activity, the stock is currently trending on the back of news regarding infrastructure expansion and institutional investment, fueling speculation about its long-term role in domestic industrial independence.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin is attracting significant attention as investors highlight its role as an AI-powered infrastructure project on the Base ecosystem, with community members actively discussing its long-term potential as an undervalued asset. The sentiment is fueled by consistent development updates from the team and strong ecosystem volume, leading many to hold through market volatility in anticipation of future price appreciation.

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A. Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.

Karyopharm Therapeutics Inc

Karyopharm Therapeutics is currently trending due to the completed enrollment of its Phase 3 SENTRY trial for myelofibrosis, though community discussion remains deeply polarized by frustration over persistent financial instability and long-standing concerns regarding executive leadership. Investors are actively debating the potential for a clinical turnaround against the backdrop of an extended cash runway and the company's challenging historical performance.

Select Sector SPDR Trust (The) - State Street Industrial Select Sector SPDR ETF

Industrial Select Sector SPDR Fund

The Industrial Select Sector SPDR Fund (XLI) is seeing significant community focus as technical analysts leverage Elliott Wave strategies to identify and trade within high-probability reaction zones. While some investors are concerned about broader economic headwinds and sector rotation, others remain bullish, viewing current pullbacks as strategic entry points for long-term industrial exposure.

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Phathom Pharmaceuticals Inc

Phathom Pharmaceuticals is trending as investors monitor institutional accumulation and signs of a potential short squeeze amid anticipation of profitability in the coming quarters. The community is actively discussing the drug's strong prescription growth and its long-term potential as an acquisition target for larger pharmaceutical firms.

Kraken Robotics, Inc. engages in the design, manufacture, and sale of software-centric sensors, subsea batteries, thrusters and underwater robotic systems. It operates through the following geographical segments: Asia Pacific, Europe, Middle East and Africa, North America, and Other. The company was founded on May 14, 2008, and is headquartered in Mt. Pearl, Canada.

Kraken Robotics Inc

Kraken Robotics is seeing significant community interest driven by its strategic acquisition of Covelya Group, which bolsters its subsea technology platform, and heightened geopolitical focus on critical underwater infrastructure protection. Investors are actively discussing the company's long-term defense sector role, its potential for major exchange uplisting, and strong revenue growth outlook.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of pharma giant Eli Lilly &amp; Co (LLY) jumped over 13% on Thursday after the company surpassed Wall Street’s second-quarter estimates and raised its full-year guidance.The firm reported earnings per share (EPS) of $3.92 compared to an estimate of $2.60 while revenue came in at $11.30 billion versus an estimate of $9.92 billion.However, the highlight of the earnings report came in the form of an increase in its full-year guidance by $3 billion to the range of $45.40 billion to $46.60 billion. Management’s upgraded outlook was primarily driven by the strong performance of Mounjaro and Zepbound, as well as the firm’s non-incretin medicines.Eli Lilly also increased its EPS guidance to the range of $15.10 to $15.60 on a reported basis compared to a previous guidance of $13.05 to $13.55. Non-GAAP EPS is expected to come in at $16.10-16.60 compared to prior guidance of $13.50-14.00.Following the upbeat announcement, retail sentiment on Eli Lilly continued to trend in the ‘bullish’ territory (65/100) amid ‘high’ message volumes.<figure class="image"><a href="https://stocktwits.com/symbol/LLY"><img style="aspect-ratio:1882/522;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_08_08_at_9_19_54_AM_bfa85cd852.png" alt="Eli Lilly sentiment meter as of 8:48 a.m. EST on August 08, 2024" width="1882" height="522"></a><figcaption>Eli Lilly sentiment meter as of 8:48 a.m. EST on August 08, 2024</figcaption></figure>David A. Ricks, Lilly's chair and CEO said Mounjaro, Zepbound and Verzenio led the firm’s strong financial performance during the quarter. "We also recently received approval of Kisunla to help people with Alzheimer's disease, a moment that was decades in the making,” he said.During the second quarter, worldwide Mounjaro revenue stood at $3.09 billion versus $979.70 million in Q2 2023. Mounjaro is an injectable medicine for type-2 diabetes in adults. Zepbound, which launched in the U.S. for the treatment of adult patients with obesity or overweight with weight-related co-morbidities, saw U.S. revenue come in at $1.24 billion.The firm’s pipeline progress included approval of Kisunla in the U.S. for Alzheimer's disease and Jaypirca in Japan for relapsed or refractory mantle cell lymphoma.Some Stocktwits users, including "HighBetaAlgorithms" are bullish on the stock given that obesity has been a widespread problem in the U.S. and a growing concern globally.<stembedurl>https://stocktwits.com/HighBetaAlgorithms/message/582263226</stembedurl>

Eli Lilly reported earnings per share of $3.92 compared to an estimate of $2.60

Eli Lilly Raises Full-Year Guidance By Whopping $3 Billion, Draws Retail Cheer

The major highlight of the pharmaceutical giant’s earnings came in the form of an increase in its full-year guidance by $3 billion to the range of $45.40 billion to $46.60 billion. 

Eli Lilly Raises Full-Year Guidance By Whopping $3 Billion

Equity

The major highlight of the pharmaceutical giant’s earnings came in the form of an increase in its full-year guidance by $3 billion to the range of $45.40 billion to $46.60 billion. The upgraded outlook was primarily driven by the strong performance of Mounjaro and Zepbound, as well as the firm’s non-incretin medicines.

CURE
Direxion Daily Healthcare Bull 3X Shares

Feed

News

Sentiment

Fundamentals

Info

Compact View

Latest CURE News

CUREDirexion Daily Healthcare Bull 3X Shares